The vaccine alliance, Gavi, announced on July 5th that twelve African nations would be receiving 18 million doses of the first-ever malaria vaccine over the next two years. These vaccines will be essential in saving lives because malaria is one of the main killers on the African continent.
Priority has been given to the regions that are most in need and where the danger of malaria disease and mortality among children is highest because the vaccine supply will initially be restricted.
Representatives from the Gavi Secretariat, UNICEF, WHO, the Africa Centers for Disease Control and Prevention (Africa CDC), and civil society organizations also make up the Framework implementation group that created the procedure for administering the vaccine. The vaccinations against malaria are produced by Indian firms.
The annual need for malaria vaccine will increase to 40–60 million doses by 2026, and 80–100 million doses by 2030. In the future, the RTS, S/AS01 vaccine will be provided by Bharat Biotech.
The production of the protein component of the malaria vaccine RTS, S/AS01 will be shifted to India's Bharat Biotech in 2021, according to GSK, the British pharmaceutical corporation that has collaborated with charity organization PATH for more than three decades.
Working with an established leader like Bharat Biotech will help safeguard the long-term future of the only vaccine now available, which is essential for the ongoing fight against this fatal illness, according to Thomas Breuer of GSK at the time. Bharat Biotech, based in Hyderabad, is now the only source for the RTS.
accine and is anticipated to stay that way until 2029.
To support the pilot program for the WHO, GSK has pledged to contribute 10 million doses of the vaccine.
The Serum Institute of India (SII) will produce and supply a second vaccine known as R21/Matrix-M that was created by Oxford University and may also soon be prequalified by WHO, according to GAVI.
The R21/Matrix-M malaria vaccine, created by Oxford University and produced by the Serum Institute of India, received regulatory permission for use by the government of Ghana in April of this year. 200 million doses per year's worth of manufacturing capacity have already been built by SII. A low-dose vaccine called R21/Matrix-M is administered to kids between the ages of 5 and 36 months. It has regularly complied with the WHO's 75% standard.
It should be noted that India is the world's top producer of affordable vaccines. In India's struggle against Covid, Serum Institute of India and Bharat Biotech both had a significant impact.
Malaria vaccination campaign in African nations
The Global Fund to Fight AIDS, Tuberculosis, and Malaria (Gavi) and United are funding the delivery of malaria vaccinations through WHO to Ghana, Kenya, and Malawi. Since 2019, 1.7 million kids in these nations have received the RTS, S/AS01 vaccination, which has demonstrated noteworthy effects and significantly decreased the incidence of severe malaria. Malaria-related mortality among youngsters have decreased as well. 28 nations have expressed interest in obtaining the malaria vaccine thus far.
With an anticipated supply of 18, Nine additional nations will receive the vaccine, including Benin, Burkina Faso, Burundi, Cameroon, the Democratic Republic of the Congo, Liberia, Niger, Sierra Leone, and Uganda, totaling one million doses. For the first time, the vaccine will be included in these nations' regular immunization programs.
The first doses of the vaccine will arrive in these nations between October and December 2023 thanks to the first tranche of allocation to Gavi through UNICEF. Early in 2024, the vaccine dissemination will start.
"This vaccine has the potential to be very impactful in the fight against malaria, and when widely implemented alongside other interventions, it can prevent tens of thousands of future deaths," said Thabani Maphosa, managing director of country programs delivery at Gavi. each year. As we expand to a new total of 12 nations, we must ensure that the doses we do have are used as effectively as possible while working with manufacturers to help ramp up supply. To do this, we must apply all the lessons we've learned from our pilot programs.
Every year, millions of African children under the age of five lose their lives to malaria.
One of the worst infections, malaria kills almost a million children under the age of five in Africa every year. In 2023, these fatalities represented 95% of all cases of malaria worldwide and 95% of all malaria-related deaths. Ephrem T. Lemango, Associate Director of Immunization at UNICEF, stated: "Nearly every minute, a child under five is immunized. ages, passes away from malaria. These deaths have long been curable and preventable, but the introduction of this vaccination will increase children's chances of survival, particularly in Africa. We hope that as supply grows, many more kids will gain from this life-saving development.
"The malaria vaccine is a breakthrough to improve child health and child survival, and families and communities, rightly, want this vaccine for their children," said WHO Director of Immunization, Vaccines, and Biologicals. The youngsters who are most at risk of contracting malaria will receive the first round of vaccination shots. The strong reach of childhood immunization and the significant demand for the vaccine will enhance access to malaria prevention equity and help save a lot of young lives. Up until all at-risk children have access, we will put forth unwavering effort to improve supply.
You must be logged in to post a comment.